Bio News
U.S.-based Amgen said its investigational drug candidate dazodalibep for the autoimmune disease Sjögren disease met its primary endpoint in a phase 3 clinical trial.
Dazodalibep is a fusion protein that targets CD40 ligand and significantly improved disease activity scores compared with placebo after 48 weeks of treatment.
Amgen plans to disclose detailed results at a future medical conference.
BIOBOOK TEAM
biobookmedia@biobook.co.krRoche’s New Drug for Uveitic Macular Edema Faces FDA Decision in July 2027
BMS Reports Concurrent Phase 3 Success in Idiopathic Pulmonary Fibrosis and Solid Tumors
Merck’s $1.3 trillion eye disease drug raises safety and efficacy concerns: “Limited competitiveness”
CHA Biotech Holds 24.23% Stake in CMG Pharmaceutical as Share Consolidation Reduces Its Share Count
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
MFDS Begins Distribution of Internationally Certified Reference Materials, Including 24 New Items, for a Total of 882
